miR-7 inhibits tumor metastasis and reverses the epithelial–mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer [113]. This evidence concerns the gene EGFR and ovarian carcinoma.